Efficacy and Safety of Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin in pMMR/MSS Locally Advanced Middle and Low Rectal Cancer: An Open, Multi-center, Prospective, Single-arm Phase II Clinical Study

This is an open, prospective, multi-center, single-arm phase II clinical study assessing the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin in patients with pMMR/MSS locally advanced middle and low rectal cancer.

开始日期2023-12-01

申办/合作机构

北京友谊医院

[+1]

NCT06024356 / Not yet recruitingN/AIIT

Efficacy and Safety of Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer: a Single-center, Retrospective, Controlled Study

It is a single-center, retrospective, controlled study to investigate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer.

开始日期2023-09-20

申办/合作机构

北京友谊医院

NCT06178146 / Recruiting临床4期IIT

A Prospective, Open, Randomized Controlled Stage II Trial Investigating the Efficacy and Safety of Thymosin Alpha-1 in Treating Moderate to Severe Immune-related Adverse Events

Thymosin alpha-1 (Tα-1) has shown clinical benefits in patients whose immune functions are severely compromised or ineffective. Therefore, this study is attempted to explore whether Tα-1 could be used as a therapeutic option for the treatment of immune-related adverse events (irAEs).

开始日期2023-09-01

申办/合作机构

山东省千佛山医院

100 项与胸腺法新相关的临床结果

登录后查看更多信息

100 项与胸腺法新相关的转化医学

登录后查看更多信息

100 项与胸腺法新相关的专利（医药）

登录后查看更多信息

886

项与胸腺法新相关的文献（医药）

2024-03-01·BMJ Open

Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study)

Article

作者: Zhang, Liyuan ; Zhang, Chenyang ; Xu, Meiling ; Hong, Zhihui ; Ma, Yifu ; Peng, Yong ; Chen, Rongzheng ; Chen, Guangqiang ; Zhao, Xiangrong ; Kong, Yuehong ; Dai, Xiaoxiao ; Xing, Pengfei ; Zhang, Junjun ; Zhang, Hong

IntroductionThe PRaG regimen, which consists of hypofractionated radiotherapy combined with a programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor and granulocyte-macrophage colony stimulating factor (GM-CSF), has been demonstrated to have a survival benefit in patients with advanced solid tumours who have failed at least two lines of treatment. Nonetheless, lymphopenia poses an impediment to the enduring efficacy of PD-1/PD-L1 inhibitor therapy. Adequate lymphocyte reserves are essential for the efficacy of immunotherapy. Coupling the PRaG regimen with immunomodulatory agents that augment the number and functionality of lymphocytes may yield further survival benefits in this cohort of patients.ObjectiveThe aim of this study is to investigate the effectiveness and safety of a meticulously thymalfasin-controlled PRaG regimen in patients with advanced and chemotherapy-resistant solid tumours.Methods and analysisThe study has a prospective, single-arm, open-label, multicentre design and aims to recruit up to 60 patients with histologically confirmed advanced solid tumours that have relapsed or metastasised. All eligible patients will receive a minimum of two cycles of the PRaG regimen comprising thymalfasin followed by maintenance treatment with a PD-1/PD-L1 inhibitor and thymalfasin for 1 year or until disease progression. Patients will be monitored according to the predetermined protocol for a year or until disease progression after initiation of radiotherapy.Ethics and disseminationThe study protocol was approved by the Ethics Committee of the Second Affiliated Hospital of Soochow University, on 25 November 2022 (JD-LK-2022-151-01) and all other participating hospitals. Findings will be disseminated through national and international conferences. We also plan to publish our findings in high-impact peer-reviewed journal.Trial registration numberNCT05790447.

2024-01-31·Alternative therapies in health and medicine

Mortality Study of Patients with Omicron Infection Before and After the Implementation of the New Crown Standard.

Article

作者: Sun, Yang ; Li, Chunhui ; Liu, Chun ; Wang, Aimin ; Liu, Wei ; Zhang, Lina ; Ma, Xinhua ; Lu, Yong

ObjectiveTo investigate the mortality rate of patients with Omicron infection before and after the implementation of the new crown standard, and to evaluate the impact of new treatment protocols on the mortality rate of patients with Omicron infection.MethodsClinical data of 1419 Omicron-infected patients treated in our hospital from April 10, 2022 to June 3, 2022 were collected(Patients diagnosed with Omicron infection who met the diagnostic criteria in the "Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 9)"15 and whose nasal/pharyngeal swab samples were typed as Omicron variants by laboratory viral genotyping). They were divided into the observation group (April 25 2022 - June 3 2022) and the control group (April 10 2022 - April 24 2022) before and after the implementation criteria. Clinical data of 1419 patients were collected and compared between the two groups on whether to use anticoagulant drugs, whether to use antiplatelet drugs, gender, whether to use new drugs of thymosin/thymus method, age, whether to use herbal medicine, whether to use Fuzheng prescription, blood routine, liver function, kidney function indicators, mortality of patients.ResultsA total of 1419 patients were initially selected; 501 patients with incomplete information were excluded, and finally, 918 patients were included. According to the time period before and after the application criteria, they were divided into an observation group (586 cases) and a control group (332 cases). There were no statistically significant differences in gender, age, antiplatelet drug use, and herbal medicine use between the two groups (P < .05). However, there were significant differences in the use of anticoagulant drugs, thymidine/thymidine drugs, and Fu Zhengfang between the two groups. It was statistically significant that the mortality rate in the observation group (2.39)% was significantly lower than that in the control group (5.12)%. P < .05 White blood cell count, red blood cell ratio, lymphocyte count, hemoglobin, neutrophil count, and neutrophil ratio were not significantly different between the two groups (P < .05) .In comparison to the control group (4.92±8.00)10^9/L, the platelet count in the observation group (4.77±3.41)109/L was considerably lower. The difference was statistically significant (P < .05). The comparison of total bilirubin, total protein values and alkaline phosphatase values between the two groups was not significant (P < .05). In the observation group, albumin (38.71±6.39) g/L, glutamate transaminase (23.93±26.03) U/L, glutathione transaminase (26.12±25.53) U/L, gamma-glutamyltransferase (34.28±52.3) U/L, globulin values (28.13±5.55) g/L were significantly lower than those of the control group (36.66±7.08) g/L, (30.36±65.77) U/L, (33.29±49.72) U/L, (43.76±80.23) U/L, (29.85±5.67) g/L, the difference was statistically significant (P < .05). Between the two groups, there were no significant differences in the values of uric acid or creatinine (P > .05). Levels and uric acid readings did not differ significantly, P > .05. The difference between the urea values of the observation group (7.44±6.34 mmol/L) and the control group (8.75±7.51 mmol/L) was statistically significant (P < .05).ConclusionAfter the implementation of the treatment protocol for COVID-19 (Trial Version 9), the number of death cases among patients with Omicron variant infection has significantly decreased. The treatment protocol is safe and feasible and can be widely applied in clinical settings..And it will further promote the development and administration of vaccines to prevent and control the spread of the novel coronavirus, reducing the occurrence of patients and death cases.

2023-12-13·Evidence-Based Complementary and Alternative Medicine

Retracted: Effect of Thymosin on Inflammatory Factor Levels, Immune Function, and Quality of Life in Lung Cancer Patients Undergoing Radical Thoracoscopic Surgery

作者: And Alternative Medicine, Evidence-Based Complementary

[This retracts the article DOI: 10.1155/2022/8749999.].

项与胸腺法新相关的新闻（医药）

2024-05-09

·药融圈

2次私有化的Biotech

▲5月30-31日第八届广州生物医药创新者峰会扫码立即报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。药融云数据（www.pharnexcloud.com）监测显示：赛生药业控股有限公司（6600.HK）（简称：赛生药业）是一家拥有产品开发和商业化集成平台的生物制药公司，战略上专注于在中国规模较大、增长迅速且存在巨大未被满足医疗需求的治疗领域，包括肿瘤科及重症感染。凭借赛生药业的产品开发及商业化实力，公司在重点治疗领域均衡和优质的上市产品及具有较佳潜力的在研产品的开发及商业化组合方面已建立良好的往绩记录。第一次私有化赛生药业前身是 SciClone US，最早成立于1990年，早期创始人为创始人Thomas E. Moore和Nelson M. Schneider；于1992 年在美国纳斯达克上市，是一家老牌上市公司。2013年新的中国管理团队加入公司，后公司在2017年被私有化。(2017年6月7日，由德福资本/GL发起、中银投资、鼎晖投资、上达资本、Boying Investment组成的买方财团Silver Biotech与SciClone US签订合并协议，以每股11.18美元的现金对价，收购SciClone US所有发行在外的普通股。)港股上市2021上市招股书，所示图片进展2021 年“全新”的赛生药业于中国香港上市，当时募集资金总额约为21.80亿港元。目前赛生药业三大业务：自有特色产品日达仙（胸腺法新的原研产品）(港股上市前2017~2019年间，日达仙分别实现销售额人民币11.26亿元、人民币11.68亿元和人民币13.49亿元)；授权引入候选新药产品（肿瘤与抗感染领域）；销售合作推广分销服务（辉瑞及百特成熟产品）。具体到新药引进/License-in合作开发方面：根据赛生药业2022年8月与美纳里尼亚太公司达成的许可及合作协议，赛生药业可根据美纳里尼与 Melinta Therapeutics, Inc. 此前签订的相关协议，在中国境内独家开发和商业化Vaborem®（注射用美罗培南韦博巴坦）。2023年3月，赛生药业递交的Vaborem®临床试验申请获得了中国国家药品监督管理局（NMPA）批准。Vaborem®在中国开展的III期临床试验于2023年7月完成首例受试者入组给药，并于2024年1月完成全部受试者入组。药融云数据www.pharnexcloud.com；截图来源该研究是在中国开展的一项随机、双盲双模拟、阳性药物对照(辉瑞的注射用哌拉西林钠他唑巴坦钠 )、多中心的III期临床试验，旨在评价Vaborem®在复杂性尿路感染（包括急性肾盂肾炎）患者中的有效性和安全性，由复旦大学附属华山医院王明贵教授和上海交通大学医学院附属仁济医院郑军华教授担任主要研究者，在全国27家研究中心共入组了108例受试者。该研究结果，及同时开展的一项在中国健康志愿者中评估Vaborem®药代动力学特征的研究结果，将用于桥接国外临床试验数据，并支持Vaborem®在中国的上市申请。其他新药布局：ORSERDU®（艾拉司群）ORSERDU®（艾拉司群）是一款口服选择性雌激素受体降解剂，用于治疗既往至少接受过一线内分泌治疗后疾病进展的雌激素受体1基因（ESR1）突变的雌激素受体（ER）阳性、人类表皮生长因子受体2（HER2）阴性晚期或转移性乳腺癌的绝经后女性和成年男性。Vibativ®(telavancin)Vibativ®是新型脂糖肽类抗生素，用于治疗金黄色葡萄球菌所致的医院获得性细菌性肺炎（HABP）与呼吸机相关细菌性肺炎（VABP），以及复杂性皮肤及皮肤软组织感染（cSSSIs）。RRx-001RRx-001是一款具有First-in-Class（FIC）潜质的小分子药物，具有多种作用机制，包括CD47-SIRPα靶向、RONs生成以及表观遗传调节。RRx-001可以对多种肿瘤微环境异常起到调节作用，包括：下调CD47-SIRPα, 使肿瘤相关巨噬细胞（TAM）复极化，由抗炎症M2表型转为促炎症 M1表型；通过表观遗传抑制活性激活抑癌基因，逆转化疗耐药；使肿瘤血管正常化以增加化疗药物渗透，产生代谢产物RONs导致肿瘤细胞坏死。OmburtamabOmburtamab是一种放射性核素碘131标记的靶向B7-H3（CD276）的单克隆抗体，靶向实体肿瘤中表达B7-H3的细胞，并结合到B7-H3分子上的生物功能的关键区域--FG环依赖型构象。药融云数据www.pharnexcloud.com；截图来源PEN-866PEN-866是一款小分子偶联药物，药物的一端为可靶向结合被激活的HSP90蛋白，另一端为拓扑异构酶抑制剂（SN-38）。PEN-866的独特桥接设计及细胞毒素释放机理使得SN-38可以特异性地在肿瘤部位聚集，同时随着连接分子的持续分解，持久地在肿瘤部位释放，并最终造成DNA的破坏及肿瘤的消退。PT-112这是一种创新型铂类小分子药物，通过细胞凋亡、免疫特性及高耐受性来抗肿瘤效果。PT-112的设计初衷是为了减少传统铂类药化疗中的毒性及耐药性。ABTL-0812这是一种具有独特作用机制的潜在候选药物。ABTL-0812通过与核受体PPARα和γ偶联来抑制PI3K/Akt/mTOR (PAM) 通路，从而诱导与Akt结合并阻碍其激活的假激酶TRIB3，并导致mTOR发生抑制，从而导致自噬依赖性癌细胞死亡。HSP90-PI3K偶联物HSP90-PI3K偶联物是一款小分子偶联药物，由磷脂酰肌醇3-激酶（PI3K）抑制剂、连接体与热休克蛋白90（HSP90）结合构成。再次被提出要约私有化2023财年，赛生药业营收为31.56亿元，同比增长约为14.8%；净利润同比增长增31.2%至11.2亿元。此前在2024年3月28日，德福资本及赛生药业联合公告：3月19日，要约人(Silver Pegasus Investment Limited)根据公司法第86条以协议安排方式将赛生药业私有化，要求董事会向计划股份持有人提呈建议，其中涉及注销计划股份，作为代价，就每股计划股份以现金向计划股东支付注销价（以换取每股计划股份现金18.8港元），并撤销股份于联交所的上市地位。注销价18.8港元较不受干扰日期收市价每股14.04港元溢价约33.90%，较最后交易日(2024年3月18日)收市价每股16.04港元溢价约17.21%。药融圈密切关注后续进展。参考：NMPA/CDE；药融云数据，www.pharnexcloud.com；FDA/EMA/PMDA；相关公司公开披露；www.sciclone.com；http://www.sciclone.com/Modules/research.aspx；https://pharma.bcpmdata.com/database/1/detail/39/Wsbrmo4B6rPXm79Mnp50?aliasId=d361ca6640；https://quote.eastmoney.com/hk/06600.html；等等。本文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场，不作任何用药推荐活动推荐 5月 • 第八届大湾区生物医药创新者峰会关键词：小分子，XDC，多肽及GLP-1热点话题，80+行业专家（点击下方图片查看详情）▼【关于药融圈】药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。

引进/卖出临床3期医药出海并购

2024-04-09

·医药笔记

中国创新药的市场格局变迁

▎Armstrong2015年722以来，中国创新药行业进入全新时代，2018年开始PD-1为代表的大分子药物、EGFR、BTK为代表的小分子新药引领整个市场的迭代演化。大分子领域，2015年之前几乎没有国产抗体药物，因此这一波伴随着抗体新药和类似药的同步爆发。类似药领域，爆款仍然以肿瘤为主，贝伐珠单抗、曲妥珠单抗、利妥昔单抗达到数十亿元乃至百亿元规模，自免的TNFα则明显小了一个数量级。齐鲁制药、复宏汉霖的抗体类似药均达到数亿元规模，信达生物也超过10亿元（具体数据未公开）。抗体新药方面，百济神州PD-1增长最快，2023年销售额38亿元，信达生物PD-1销售额28亿元。后来者中，复宏汉霖斯鲁利单抗凭借小细胞肺癌等差异化切入点快速突破10亿元，康方生物PD-1/CTLA-4双抗上市第二年实现13.8亿元销售额。荣昌生物ADC+泰它西普两款产品2023年销售额10.5亿元。康弘药业康柏西普2023年销售额接近20亿元。CAR-T领域，受限于国内的支付能力，药明巨诺、复星凯特放量缓慢。传奇生物BCMA CAR-T以BIC强势进入欧美市场，2023年销售额36亿元，前不久获批二线及以后治疗，打开更大想象空间。重组凝血因子领域，神州细胞凭借国产独家品种的地位，销售额快速破10亿元，但已经迎来国产竞品。后续该领域的看点，还有信念医药等AAV基因疗法的冲击。重组蛋白方面，三生制药TPO快速攀升，2023年销售额高达42亿元。赛生药业日达仙2023年销售额26.3亿元。特宝生物长效干扰素销售额18亿元。胰岛素领域，过去两年受到集采冲击发生一些调整，2023年通化东宝、甘李药业超过20亿元，联邦制药超过10亿元。老一代的重组蛋白药物，还有长春高新的生长激素产品等。疫苗领域，国产创新疫苗处于起步阶段，HPV疫苗、肺炎结合疫苗率先实现国产替代，肺炎结合疫苗略有下滑，HPV疫苗方面国产二价则仍无法抗衡进口的四价和九价，2023年萎缩严重，同时价格战愈发激烈。最新的创新疫苗品种当属带疱疫苗，智飞代理葛兰素史克，百克生物上一代的减毒活疫苗放量迅速，2023年销售额8.82亿元，不过这一领域仍需要新一代的重组疫苗来抗衡进口品种。流感疫苗、狂犬疫苗属于二类苗中老品种，2023年流感爆发促进华兰疫苗有较大幅度的增长，实现24亿元销售额。同时口服药奥司他韦焕发二次青春，可威2023年大卖55亿元。小分子方面，百悦泽泽布替尼凭借美国市场的优异表现，2023年大卖91亿元，成为首款国产创新药中的重磅炸弹。三代EGFR，艾力斯伏美替尼销售额突破20亿元，阿美替尼也在20亿元以上（具体数据未公开）。总结从商业角度来看，国产创新药中爆款极为有限，最大的亮点莫过于国际化成功的BIC产品泽布替尼、益基奥仑赛。差异化和竞争格局是影响市场份额的重要因素之一，PD-1/CTLA-4、斯鲁利单抗在SCLC的差异化切入、神州细胞国产独家的重组八因子等都有不错的市场表现。对于竞争激烈的品种，传统药企销售渠道优势成为难以逾越的品种，如齐鲁制药的抗体类似药，恒瑞医药的me too药等。此外，还有各种复杂原因造就的独家品种，如石药集团的丁苯酞等。对于后来者来说，差异化分子设计和适应症选择，积极融入国际市场，仍然是破局的关键。对于高价药、罕见病，国际市场甚至可能是唯一的出路。Armstrong技术全梳理系列GPRC5D靶点全梳理；CD40靶点全梳理；CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向；Claudin 6靶点全梳理；Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇；CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理；Ambrx技术全梳理；Vir Biotech技术全梳理；Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；科望医药技术全梳理2.0；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理；Momenta技术全梳理；NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

免疫疗法疫苗抗体药物偶联物细胞疗法基因疗法

2024-03-29

·Pharmaceutical Technology

Gilead’s Vemlidy expands label to treat paediatric chronic HBV

Vemlidy is approved to treat patients six years and older for chronic HBV. Credits: Sundry Photography/Shutterstock.com Soon after GSK gained traction with a US Food and Drug Administration (FDA) fast track designation for its investigational treatment bepirovirsen for chronic hepatitis B virus (HBV), Gilead Sciences has strengthened its position in the indication with an FDA approval for Vemlidy (tenofovir alafenamide) to treat paediatric patients. The once daily 25mg tablets have been greenlit to treat patients with chronic HBV with compensated liver disease that are six years and older and weigh at least 25kg. The supplemental new drug application (sNDA) approval was based on data from the ongoing Phase II Study 1092 (NCT02932150), comparing the safety and efficacy of 25mg Vemlidy to placebo in 88 treatment-naïve and treatment-experienced patients with chronic HBV. As per a 28 March press release, patients treated with Vemlidy and those that switched to open-label Vemlidy after week 24 demonstrated “progressive increases in rates of virological suppression” by week 96. “The expanded indication for Vemlidy for the treatment of children as young as six years old is a testament to the safety, tolerability and efficacy profile of this therapy,” said Dr. Frank Duff, Gilead’s senior vice president of the virology therapeutic area, in the announcement. The pharma giant aims to continue addressing unmet treatment needs for children, he added. Vemlidy, a small molecule nucleoside analogue reverse transcriptase inhibitor, was first FDA approved in 2016 as a treatment for adults with chronic HBV and gained its first label expansion in 2022 to treat patients aged 12 years and older with compensated liver disease. The product is marketed with a boxed warning for post-treatment severe acute exacerbation of hepatitis B. See Also: Angelini gets grant for method for labelling reels using robot and application roller Rohto Pharmaceutical gets grant for ophthalmic composition for treating myopia with crocetin and ginkgo leaf GlobalData’s drugs database forecasts that the hepatitis B treatment market will significantly increase over the next six years to reach $10.5bn in 2029, with analysts predicting a compound annual growth rate of 30%. According to the analysts, 71% of the sales in 2022 were attributed to Vemlidy and SciClone Pharmaceuticals’ Zadaxin, a synthetic polypeptide, indicating market dominance. GlobalData’s consensus forecasts predict that Vemlidy will generate $873m in sales in 2024. GlobalData is the parent company of Pharmaceutical Technology .

上市批准临床结果临床2期快速通道

100 项与胸腺法新相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06116	-	A05A	DB04900

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
慢性乙型肝炎	中国	Sciclone Pharmaceuticals Italy Srl	1996-01-01
乙型肝炎	-	-	-
丙型肝炎	-	-	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床2期	中国	SciClone Pharmaceuticals LLC	2023-04-01
肿瘤	临床2期	中国	SciClone Pharmaceuticals LLC	2023-04-01
肝细胞癌	临床前	美国	SciClone Pharmaceuticals LLC	2004-04-28
终末期肾脏病	药物发现	意大利	Alfasigma SpA	2009-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04487444 (Pubmed)	临床2期	新型冠状病毒感染	49	Thymalfasin (Tα1)	(構選醖齋構簾衊襯鹽鏇) = Nine serious adverse events among treated patients were deemed not related to Tα1. 鹹壓獵餘構積艱顧衊觸 (獵繭餘糧網繭鑰淵築窪 ) 更多	积极	2022-09-03
				Thymalfasin (Tα1) (Standard of care)
Pubmed \| J Cardiothorac Surg	临床4期	-	160	Single-dose group (TA1)	淵鑰齋獵範獵願鬱願範(糧壓襯積齋製範糧簾築) = 14 (8.8%) had acute kidney failure 觸鏇窪衊積鹹鹽範壓範 (糧憲願壓壓淵淵壓願遞 ) 更多	-	2011-10-14
				Double-dose group (TA2)
ASCO2005	N/A	晚期乳腺癌	18	thymalfasin (Group 1)	(艱齋糧憲繭觸選鏇繭遞) = 夢襯範範衊夢觸範醖簾網糧糧淵鹽構構構襯齋 (餘鏇餘鏇獵憲膚製鬱觸 )	-	2005-06-01
				thymalfasin (Group 2)	(壓製襯壓糧遞觸鬱簾窪) = 艱鑰繭餘積構襯壓簾鑰遞顧鬱繭壓鹹蓋憲顧製 (壓鏇選壓範鏇艱壓構範 )